Prevention of bacterial endocarditis. A statement for health professionals by the Committee on Rheumatic Fever and Bacterial Endocarditis of the Council on Cardiovascular Diseases in the Young of the American Heart Association.
D000573:American Hospital Association; D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006348:Cardiac Surgical Procedures; D003814:Dentistry, Operative; D004697:Endocarditis, Bacterial / Q000517:prevention & control*; D005260:Female; D005767:Gastrointestinal Diseases / Q000628:therapy; D005831:Genital Diseases, Female / Q000628:therapy; D005832:Genital Diseases, Male / Q000628:therapy; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010404:Penicillin V / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control; D011292:Premedication; D012140:Respiratory Tract Diseases / Q000601:surgery; D012306:Risk; D018805:Sepsis / Q000517:prevention & control; D014481:United States; D014640:Vancomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D014640:Vancomycin; D000667:Ampicillin; D010404:Penicillin V